Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Stanford University
University Medical Center Goettingen